IPP Bureau
Lupin receives USFDA nod for Famotidine injection
By IPP Bureau - May 15, 2026
Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market
Indoco Remedies' Baddi plant gets EU GMP approval from Malta Medicines Authority
By IPP Bureau - May 15, 2026
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
Alembic Pharma receives USFDA tentative approval for Darolutamide tablets
By IPP Bureau - May 15, 2026
Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States
Telangana life sciences ecosystem reaches $145 billion valuation
By IPP Bureau - May 15, 2026
The state has received Rs. 84,000 crore investments in the sector over two years, positioning Hyderabad among the world’s leading life sciences clusters
Senores Pharma reports 62% rise in FY26 total income to Rs. 664 crore
By IPP Bureau - May 15, 2026
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
OneSource records Rs. 4,282 million revenue in Q4 FY26
By IPP Bureau - May 15, 2026
Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold
Merck to showcase 100+ oncology studies at 2026 ASCO meeting
By IPP Bureau - May 14, 2026
Highlighting KEYTRUDA & expanding cancer pipeline
Wegovy delivers consistent weight loss & heart benefits for women across menopause: Novo Nordisk study
By IPP Bureau - May 14, 2026
Nearly one in five women worldwide are now living with obesity
Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook
By IPP Bureau - May 14, 2026
Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros
Shilpa Medicare signs long-term CDMO pact with NXI Therapeutics to expand global biotech push
By IPP Bureau - May 14, 2026
Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support
Neuland Laboratories posts blockbuster FY26 performance
By IPP Bureau - May 14, 2026
Merck KGaA raises 2026 outlook as life science & AI chip boom power strong Q1 growth
By IPP Bureau - May 14, 2026
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
Pfizer scores landmark EU approval for hemophilia drug HYMPAVZI
By IPP Bureau - May 14, 2026
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
Revvity wins FDA clearance for total testosterone test
By IPP Bureau - May 14, 2026
